<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804345</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/67</org_study_id>
    <nct_id>NCT04804345</nct_id>
  </id_info>
  <brief_title>AProtinin Versus Tranexamic Acid in Cardiac Surgery Patients With High-risk for Excessive Bleeding</brief_title>
  <acronym>APACHE</acronym>
  <official_title>AProtinin Versus Tranexamic Acid in Cardiac Surgery Patients With High-risk for Excessive Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this before-after multicenter study the authors tested the hypothesis that the&#xD;
      prophylactic use of aprotinin compared to tranexamic acid could reduce the proportion of&#xD;
      patients presenting severe perioperative bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative bleeding remains a real challenge for physicians managing cardiac surgical&#xD;
      patients. In patients at high risk for excessive bleeding the prophylactic use of&#xD;
      antifibrinolytics may be useful. This study propose to compare the efficacity and innocuity&#xD;
      of aprotinin and tranexamic acid to reduce the proportion of patient presenting severe&#xD;
      peri-operative bleeding according the Universal Definition of Perioperative Bleeding (UDPB)&#xD;
      classification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with severe peri-operative bleeding</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>Proportion of patients with severe peri-operative bleeding defined by an UDPB (the Universal Definition of Perioperative Bleeding ) classification of 3 and 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>distribution of patients by UDPB classification category</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>proportion of patients with category 0 UDPB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of patients by UDPB classification category</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>proportion of patients with category 1 UDPB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of patients by UDPB classification category</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>proportion of patients with category 2 UDPB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of patients by UDPB classification category</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>proportion of patients with category 3 UDPB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of patients by UDPB classification category</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>proportion of patients with category 4 UDPB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>24 hours after chest closure</time_frame>
    <description>post operative chest tube blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rescue surgery for bleeding</measure>
    <time_frame>day 30 after surgery</time_frame>
    <description>proportion of rescue surgery for bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>through intensive care unit discharge, an average of 30 days</time_frame>
    <description>intensive care unit length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>through hospital discharge, an average of 30 days</time_frame>
    <description>hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KDIGO score greater than or equal to 2</measure>
    <time_frame>day 7 after surgery</time_frame>
    <description>acute kidney injury defined by KDIGO score greater than or equal to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation time</measure>
    <time_frame>through intensive care unit discharge, an average of 30 days</time_frame>
    <description>duration of artificial ventilation (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>need to use mechanical ventilation for more than 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for transfusion</measure>
    <time_frame>up to 48 hours after surgery</time_frame>
    <description>need for labil blood products and medicinal products derived from blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for transfusion</measure>
    <time_frame>up to seven day after surgery</time_frame>
    <description>need for labil blood products and medicinal products derived from blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for vasopressors/inotropes</measure>
    <time_frame>beyond 24 hours after surgery</time_frame>
    <description>need for use postoperative vasopressors/inotropes for more than 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital status</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>mortality after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new renal replacement therapy</measure>
    <time_frame>up to day 30 after surgery</time_frame>
    <description>need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short term mechanical circulatory support</measure>
    <time_frame>up to 30 day after surgery</time_frame>
    <description>need for short term mechanical circulatory support (extra corporeal life support, Impella TM pump, intra aortic balloon pump)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>up to 30 day after surgery</time_frame>
    <description>occurrence of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embolic or thrombotic event</measure>
    <time_frame>up to 30 day after surgery</time_frame>
    <description>occurrence of embolic or thrombotic event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>up to 30 day after surgery</time_frame>
    <description>occurrence of stroke</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <condition>High Risk Bleeding</condition>
  <arm_group>
    <arm_group_label>The aprotinin group,</arm_group_label>
    <description>all patients receiving a first infusion 1M KIU before surgical incision followed by a steady dose of 250 000 KIU/h with an additional dose of 1M KIU added to the cardiopulmonary bypass unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The tranexamic acid group</arm_group_label>
    <description>all patient receiving tranexamic acid following each local center standarded protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>retrospective study: standard of care</description>
    <arm_group_label>The aprotinin group,</arm_group_label>
    <arm_group_label>The tranexamic acid group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients undergoing cardiac surgery with a high risk of hemorrhage who have&#xD;
        received a prophylactic infusion of either tranexamic acid or aprotinin and meeting the&#xD;
        protocol criteria between july 2017 and october 2020 in seven university hospital centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients undergoing cardiac on pump surgery at high risk for bleeding defined by :&#xD;
&#xD;
          -  Aorto-coronary bypasses surgery (2 or more) under dual platelet aggregation therapy&#xD;
             (Primary or redo)&#xD;
&#xD;
          -  Heart transplant (Primary or Redo)&#xD;
&#xD;
          -  Infectious endocarditis (Primary or Redo)&#xD;
&#xD;
          -  Ascending acute aortic dissection (Primary or Redo)&#xD;
&#xD;
          -  Artificial heart / LVAD under CEC (Primary or Redo)&#xD;
&#xD;
          -  Combined surgery, Redo&#xD;
&#xD;
          -  Ascending aorta surgery, Redo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Off pump cardiac surgery&#xD;
&#xD;
          -  Patient not meeting the inclusion criteria&#xD;
&#xD;
          -  Patient not receiving antifibrinolytic therapy&#xD;
&#xD;
          -  Patient with absolute contraindication to antifibrinolytics,&#xD;
&#xD;
          -  Patient refusing to give access to their medical chart,&#xD;
&#xD;
          -  Patient not meeting the inclusion criteria&#xD;
&#xD;
          -  Patient protected by the law, under guardianship or trusteeship,&#xD;
&#xD;
          -  Patient deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre OUATTARA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre OUATTARA, MD, PhD</last_name>
    <phone>557656866</phone>
    <phone_ext>+33</phone_ext>
    <email>alexandre.ouattara@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien BEDAGUE, MD</last_name>
      <phone>476767010</phone>
      <phone_ext>+33</phone_ext>
      <email>DBedague@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc FELLAHI, MD, PhD</last_name>
      <phone>472118933</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-luc.fellahi@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GAUDARD, MD</last_name>
      <phone>467335958</phone>
      <phone_ext>+33</phone_ext>
      <email>p-gaudard@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand ROZEC, MD, PhD</last_name>
      <phone>240165304</phone>
      <phone_ext>+33</phone_ext>
      <email>bertrand.rozec@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Val de Seine Paris University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PROVENCHERE</last_name>
      <phone>140258080</phone>
      <phone_ext>+33</phone_ext>
      <email>sophie.provenchere@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georges Pompidou European University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard CHOLLEY, MD, PhD</last_name>
      <phone>156092515</phone>
      <phone_ext>+33</phone_ext>
      <email>bernard.cholley@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre OUATTARA, MD, PhD</last_name>
      <phone>557656866</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandre.ouattara@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre OUATTARA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>massive peri-operative bleeding</keyword>
  <keyword>antifibrinolytics</keyword>
  <keyword>blood products transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

